These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 22837197)
1. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197 [TBL] [Abstract][Full Text] [Related]
2. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768 [TBL] [Abstract][Full Text] [Related]
3. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. Seo SU; Kwon HJ; Song JH; Byun YH; Seong BL; Kawai T; Akira S; Kweon MN J Virol; 2010 Dec; 84(24):12713-22. PubMed ID: 20943980 [TBL] [Abstract][Full Text] [Related]
4. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
5. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. Nagai M; Moriyama M; Ichinohe T mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617 [TBL] [Abstract][Full Text] [Related]
6. Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis. Ato M; Takahashi Y; Fujii H; Hashimoto S; Kaji T; Itamura S; Horiuchi Y; Arakawa Y; Tashiro M; Takemori T Vaccine; 2013 Apr; 31(17):2184-90. PubMed ID: 23434386 [TBL] [Abstract][Full Text] [Related]
7. Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine. Geeraedts F; ter Veer W; Wilschut J; Huckriede A; de Haan A Vaccine; 2012 Oct; 30(45):6501-7. PubMed ID: 22841974 [TBL] [Abstract][Full Text] [Related]
9. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity. Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T Front Immunol; 2020; 11():1207. PubMed ID: 32636840 [TBL] [Abstract][Full Text] [Related]
10. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus. Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758 [TBL] [Abstract][Full Text] [Related]
11. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. Geeraedts F; Goutagny N; Hornung V; Severa M; de Haan A; Pool J; Wilschut J; Fitzgerald KA; Huckriede A PLoS Pathog; 2008 Aug; 4(8):e1000138. PubMed ID: 18769719 [TBL] [Abstract][Full Text] [Related]
12. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Quan FS; Huang C; Compans RW; Kang SM J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294 [TBL] [Abstract][Full Text] [Related]
13. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R mBio; 2017 Sep; 8(5):. PubMed ID: 28928215 [TBL] [Abstract][Full Text] [Related]
14. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice. Zhang AJ; Li C; To KK; Zhu HS; Lee AC; Li CG; Chan JF; Hung IF; Yuen KY Clin Vaccine Immunol; 2014 Apr; 21(4):570-9. PubMed ID: 24521786 [TBL] [Abstract][Full Text] [Related]
16. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978 [TBL] [Abstract][Full Text] [Related]
17. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]
18. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus. Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021 [TBL] [Abstract][Full Text] [Related]
19. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. Kulkarni RR; Rasheed MA; Bhaumik SK; Ranjan P; Cao W; Davis C; Marisetti K; Thomas S; Gangappa S; Sambhara S; Murali-Krishna K J Virol; 2014 Dec; 88(24):13990-4001. PubMed ID: 25253340 [TBL] [Abstract][Full Text] [Related]
20. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]